Nat Med. 2026;32(7):2410-2419.
Electronic cigarette use after smoking cessation and lung cancer risk.
제1저자 김연욱 · 교신저자 김연욱
소속 (7)
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. kimyw@snu.ac.kr.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. kimyw@snu.ac.kr.
- Big Data Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Seoul National University College of Medicine, Seoul, Republic of Korea.
Abstract
Electronic cigarettes (e-cigarettes) have gained popularity as a less harmful alternative to conventional cigarettes, yet their associations with lung cancer risk after smoking cessation remain uncertain. Here we evaluated 4,524,895 adults with a conventional smoking history who participated in the Korean National Health Screening Program in 2018 (baseline), with prior records from 2012-2014. Participants were classified as current smokers, short-term quitters or long-term quitters, and followed up to December 2023. Daily e-cigarette use at baseline was used to define post-cessation e-cigarette use. Lung cancer incidence and lung cancer-specific death (LCSD) were assessed using multivariable Cox models. Over 24,182,543 person-years, 35,887 lung cancers and 12,807 LCSD events occurred. Compared with complete quitters, e-cigarette use after smoking cessation was associated with higher risks of lung cancer incidence (adjusted hazard ratio (aHR) 1.56, 95% confidence interval (CI) 1.24-1.97) and LCSD (aHR 2.00, 95% CI 1.28-3.15). Associations were directionally consistent in short-term and long-term quitters and were prominent in the high-risk subgroup (incidence: aHR 1.91, 95% CI 1.44-2.53; LCSD: aHR 1.92, 95% CI 1.13-3.24). Although causality cannot be established, these findings suggest that e-cigarette use after smoking cessation may attenuate the benefits of complete cessation for lung cancer prevention.
© 2026. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: Y.W.K. has received honorarium from AstraZeneca, and research grants not related to this study from AstraZeneca. The other authors declare no competing interests.
그 밖의 정보
- 출판 형태
- Journal Article
- 저널
- Nature medicine · eISSN 1546-170X
- 전자 출판
- 2026-06-08
- MeSH
- Humans · Lung Neoplasms* / epidemiology / etiology / mortality · Smoking Cessation* · Female · Electronic Nicotine Delivery Systems* · Middle Aged · Male · Republic of Korea / epidemiology · Incidence · Risk Factors · Adult · Vaping* / adverse effects / epidemiology · Proportional Hazards Models · Aged
- 참고문헌
- 55편